Document is current
Any future updates will be listed below
-
Authors
Walsh, Thomas J.
Coleman, Craig I.
Johnson, Melissa D.
Lovelace, Belinda
Alexander, Barbara D.
-
Funding
Funding for this research was provided by:
F2G, Inc.
- License Information
-
More Information
Article History
Received: 29 September 2025
Accepted: 30 December 2025
First Online: 13 January 2026
Declarations
:
: The funder of this study had no role in the decision to publish this work. B.L. is an employee of F2G, Inc. and served as an author on this paper. B.D.A.: Consultant: Scynexis, GSK, Astellas, Merck, HealthTrackRx, Basilea, F2G, Inc.; Research Grant to My Institution: Karius; Clinical Trials (Site PI/Study PI): Scynexis, F2G, Inc.; Royalties (Chapter Author): UpToDate. M.J.: Research Grant to my Institution: Scynexis; Author Royalties: UpToDate; Licensed Technology: Biomeme, Patent Pending for gene expression classifiers of fungal infection. B.L.: Employee of F2G, Inc. C.I.C.: Consultant: F2G, Inc. TJW has received grant funding and consulting fees from the Henry Schueler Foundation; F2G, Inc., Omeros, Abbott Laboratories, Partner Therapeutics, Scynexis, Statera, T2 Biosystems, Shionogi, and Basilea. He has a leadership or fiduciary role at Medical Mycological Societies of the Americas, Center for Innovative Therapeutics and Diagnostics, ISHAM/ECMM Osteoarticular Mycoses Working Group, Henry Schueler Foundation, Save Our Sick Kids Foundation and the Mycoses Study Group Education and Research Consortium (MSG-ERC).
